Shenzhen-based QuantumPharm Inc. (HKG: 2228), better known as Xtalpi Inc., has announced that its subsidiary Ailux Biologics has struck a partnership with UCB (EBR: UCB), granting the Belgian biopharma commercial rights to utilize Ailux’s XtalFold AI platform for the discovery and engineering design of macromolecular drugs. No financial details were disclosed.
Ailux Biologics and AI Platforms
Ailux Bio, the macromolecular drug discovery unit of Xtalpi, is equipped with a proprietary database, AtlAX, and three major AI platforms. These include the structural modeling platform XtalFold, the generative protein big language model XenProT, and the macromolecular drug property prediction platform Xentient. These platforms are designed to accelerate the discovery and development of innovative macromolecular drugs.
Significance of the Partnership
This partnership between Ailux Biologics and UCB highlights the growing importance of AI in drug discovery and development. By leveraging Ailux’s advanced AI platforms, UCB aims to enhance its capabilities in discovering and engineering macromolecular drugs, potentially leading to more effective treatments for various diseases.-Fineline Info & Tech
